Purpose: To determine the prevalence of Her-2 overexpression in breast cancer and its features. Second highlight what is new and applicable in our setting. Material and methods: Data of all immunohistochemically typed blocks for breast cancer was pulled and only those negative for Estrogen receptor (ER), progesterone receptor (PgR) and Her 2 neu receptor (HER-2) amplification positive were used. Results: A total of 417 patients with Invasive Ductal Carcinoma of the breast participated, because we have an unscreened population with poor mammography screening penetrance, most cases came in as invasive ductal carcinoma. Majority were females 98.3%. More than half of respondents 60.2% were between 31 and 50 years old (Table 1). The mean age was 44.6 ± 6.4 years. Ten were HER-2 type making up 2.4% (table 2). All of them were females (Table 3). Majority 7 (70%) were found in the 41-50 years age group (Table 4). Six (6) had stage 3 disease while 4 (40%) had clinically detectable metastases mostly to the lungs with two also having central nervous system involvement in addition. Trastuzumab was recommended but only 3 (30%) could afford it and are still alive 2 years post treatment with a two having stage 2 disease and one with stage 3 disease, while the rest 6 had paclitaxel neoadjuvant chemotherapy without trastuzumab and half has passed away within 24 months leaving only 3 with terminal disease and central nervous system metastases. Conclusion: Most presented late at stage 3 or 4 as premenopausal, and survival was poor at 59% of stage 3. Trastuzumab was extremely beneficial where it was affordable.